• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.对新型环脂肽LY146032具有抗性的细菌的体外筛选
Antimicrob Agents Chemother. 1988 Jan;32(1):24-6. doi: 10.1128/AAC.32.1.24.
2
In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.LY146032(达托霉素)对特定需氧菌的体外活性。
Eur J Clin Microbiol. 1987 Feb;6(1):91-6. doi: 10.1007/BF02097209.
3
Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.LY146032(达托霉素)对革兰氏阳性球菌的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):96-9. doi: 10.1007/BF02097210.
4
LY146032: activity and resistance development in vitro.LY146032:体外活性及耐药性发展
J Antimicrob Chemother. 1987 Oct;20(4):513-7. doi: 10.1093/jac/20.4.513.
5
Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.MX-2401 的抗菌特性,一种在肺表面活性剂存在下具有广谱活性的脂肽。
Antimicrob Agents Chemother. 2011 Aug;55(8):3720-8. doi: 10.1128/AAC.00322-11. Epub 2011 May 16.
6
In vitro activity of LY146032 (daptomycin), a new peptolide.新型缩酚肽LY146032(达托霉素)的体外活性
Eur J Clin Microbiol. 1987 Feb;6(1):84-90. doi: 10.1007/BF02097208.
7
Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.LY146032与其他八种抗生素对从儿童中分离出的革兰氏阳性菌的体外活性比较
J Antimicrob Chemother. 1987 Aug;20(2):203-7. doi: 10.1093/jac/20.2.203.
8
Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.新型脂肽类抗菌药物LY146032(达托霉素)的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):100-3. doi: 10.1007/BF02097211.
9
Activity of daptomycin against enterococci and coagulase-negative staphylococci (CNS): relationship between CNS susceptibility and slime production.
J Chemother. 1993 Jun;5(3):151-4. doi: 10.1080/1120009x.1993.11739224.
10
Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens.乳酸链球菌素对多重耐药革兰氏阳性病原体的抗菌效果。
J Antimicrob Chemother. 1998 Mar;41(3):341-7. doi: 10.1093/jac/41.3.341.

引用本文的文献

1
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.达托霉素、磷霉素或两者联合治疗实验性耐甲氧西林金黄色葡萄球菌骨髓炎。
Antimicrob Agents Chemother. 2011 Nov;55(11):4999-5003. doi: 10.1128/AAC.00584-11. Epub 2011 Aug 22.
2
Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.采用转录组学和蛋白质组学相结合的方法评估临床分离的金黄色葡萄球菌菌株中达托霉素耐药的机制。
J Antimicrob Chemother. 2011 Aug;66(8):1696-711. doi: 10.1093/jac/dkr195. Epub 2011 May 28.
3
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.达托霉素对耐甲氧西林金黄色葡萄球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2003 May;47(5):1714-8. doi: 10.1128/AAC.47.5.1714-1718.2003.
4
Resistance studies with daptomycin.达托霉素的耐药性研究。
Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802. doi: 10.1128/AAC.45.6.1799-1802.2001.
5
Comparison of two techniques for measurement of in vitro killing kinetics of five antibiotics against Pseudomonas aeruginosa.两种测量五种抗生素对铜绿假单胞菌体外杀菌动力学技术的比较。
Eur J Clin Microbiol Infect Dis. 1994 May;13(5):412-7. doi: 10.1007/BF01972000.
6
Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin.
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):809-12. doi: 10.1007/BF01975057.
7
Resistance to vancomycin and teicoplanin: an emerging clinical problem.对万古霉素和替考拉宁的耐药性:一个新出现的临床问题。
Clin Microbiol Rev. 1990 Jul;3(3):280-91. doi: 10.1128/CMR.3.3.280.
8
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.

本文引用的文献

1
Some laboratory and clinical experiences with a new antibiotic, vancomycin.一种新型抗生素——万古霉素的一些实验室及临床经验
Antibiot Annu. 1956:90-106.
2
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.在琼脂中对亚抑菌浓度的诺氟沙星产生耐药性增加的微生物的快速筛选。
Antimicrob Agents Chemother. 1983 Jan;23(1):188-9. doi: 10.1128/AAC.23.1.188.
3
Penicillin-resistant variants of pneumococci.肺炎球菌的耐青霉素变体
Appl Microbiol. 1968 Feb;16(2):311-4. doi: 10.1128/am.16.2.311-314.1968.
4
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.喹诺酮抗菌剂A - 56619和A - 56620的体外活性
Antimicrob Agents Chemother. 1985 Oct;28(4):514-20. doi: 10.1128/AAC.28.4.514.
5
Emergence of vancomycin resistance in coagulase-negative staphylococci.凝固酶阴性葡萄球菌中万古霉素耐药性的出现。
N Engl J Med. 1987 Apr 9;316(15):927-31. doi: 10.1056/NEJM198704093161507.
6
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.脂肽抗生素LY146032的抗菌活性与谱,包括药敏试验建议。
Antimicrob Agents Chemother. 1987 Apr;31(4):625-9. doi: 10.1128/AAC.31.4.625.
7
In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.新型环脂肽抗生素LY146032对革兰氏阳性临床细菌的体外活性
Antimicrob Agents Chemother. 1987 Mar;31(3):455-7. doi: 10.1128/AAC.31.3.455.
8
In vitro activity of LY146032 (daptomycin), a new peptolide.新型缩酚肽LY146032(达托霉素)的体外活性
Eur J Clin Microbiol. 1987 Feb;6(1):84-90. doi: 10.1007/BF02097208.
9
Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.环肽LY146032和万古霉素的抗葡萄球菌活性。
Antimicrob Agents Chemother. 1986 Dec;30(6):938-9. doi: 10.1128/AAC.30.6.938.
10
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.LY146032对葡萄球菌、链球菌和肠球菌的体外活性。
Antimicrob Agents Chemother. 1986 Nov;30(5):781-4. doi: 10.1128/AAC.30.5.781.

对新型环脂肽LY146032具有抗性的细菌的体外筛选

In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.

作者信息

Liebowitz L D, Saunders J, Chalkley L J, Koornhof H J

机构信息

South African Medical Research Council, School of Pathology, University of the Witwatersrand, Johannesburg.

出版信息

Antimicrob Agents Chemother. 1988 Jan;32(1):24-6. doi: 10.1128/AAC.32.1.24.

DOI:10.1128/AAC.32.1.24
PMID:2831813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172091/
Abstract

Isolates of Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, and coagulase-positive and -negative staphylococci were investigated for their abilities, in vitro, to develop resistance to LY146032. Exposure of the organisms to incremental concentrations of LY146032 resulted in MICs 8- to 32-fold higher than those for the original isolates. After three passages on antibiotic-free medium, the high MICs were maintained for the coagulase-negative staphylococci and pneumococci, with a twofold decrease observed for the enterococci and a fourfold decrease observed for Staphylococcus aureus. The frequency of spontaneous emergence of resistance was highest with S. pneumoniae (1.2 X 10(-6) at 16 times the original MIC) and lowest with S. aureus (7.0 X 10(-10) at 8 times the original MIC). For bacteria For bacteria surviving time-kill studies MICs were also higher than were those for the original isolates. Exposure to LY146032 in vitro selected for strains with decreased susceptibilities to the antimicrobial agent. However, the emergence of resistance in vivo is unpredictable and can be evaluated only after prolonged clinical use of the drug.

摘要

对肺炎链球菌、粪肠球菌、屎肠球菌以及凝固酶阳性和阴性葡萄球菌的分离株进行了体外研究,以考察它们对LY146032产生耐药性的能力。将这些微生物暴露于递增浓度的LY146032中,结果其最低抑菌浓度(MIC)比原始分离株高出8至32倍。在不含抗生素的培养基上传代三次后,凝固酶阴性葡萄球菌和肺炎球菌仍保持高MIC,粪肠球菌的MIC下降了两倍,金黄色葡萄球菌的MIC下降了四倍。耐药性自发出现的频率在肺炎链球菌中最高(在原始MIC的16倍浓度下为1.2×10⁻⁶),在金黄色葡萄球菌中最低(在原始MIC的8倍浓度下为7.0×10⁻¹⁰)。对于在时间-杀菌研究中存活的细菌,其MIC也高于原始分离株。体外暴露于LY146032会选择出对抗菌剂敏感性降低的菌株。然而,体内耐药性的出现是不可预测的,只有在药物长期临床使用后才能进行评估。